Danish Pharmacovigilance Update, 16 June 2011

27 June 2011

In this issue of Danish Pharmacovigilance Update:

  • Removal of contraindication for Velcade® (bortezomib) used for the treatment of multiple myeloma
  • Interaction updates for Aptivus® (tipranavir) used for the treatment of HIV
  • New warnings for Torisel® (temsirolimus) used for the treatment of various types of cancer
  • New warning for Multaq® (dronedarone) used for treatment of atrial fibrillation
  • Risk of venous thromboembolism from the use of Yasmin® – follow-up
  • Familial adenomatous polyposis (FAP) should not be treated with celecoxib
  • Medicine and dry mouth
  • Simvastatin can cause rhabdomyolysis
  • Beware of confusion between Malarone® and Malarex®
  • Reports of heart malformations in children of mothers treated with citalopram and sertraline during pregnancy
  • Changed reimbursement rules and reported adverse reactions
  • A review of adverse reaction data for a number of medicines for treatment of dyspepsia and certain types of medicines for treatment of cardiovascular diseases after the reassessment of reimbursement in 2010

Download the newsletter in the box to the right.

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.